CLINICAL TRIALS PROFILE FOR LUNELLE
✉ Email this page to a colleague
All Clinical Trials for LUNELLE
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT01699022 ↗ | Pharmacokinetic and Pharmacodynamic Study of Cyclofem | Completed | Sun Pharmaceutical Industries Limited | Phase 1/Phase 2 | 2010-06-01 | Cyclofem® is a monthly injectable contraceptive containing 25 mg of medroxyprogesterone acetate (MPA) and 5 mg of estradiol cypionate (E2C), a long-acting ester of estradiol. The current study will assess the steady-state pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate (MPA) and estradiol (E2) after administration of Cyclofem® and will provide critical information to determine similar bioavailability of Cyclofem to Lunelle in women residing in the United States of America. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LUNELLE
Condition Name
Clinical Trial Locations for LUNELLE
Trials by Country
Clinical Trial Progress for LUNELLE
Clinical Trial Phase
Clinical Trial Sponsors for LUNELLE
Sponsor Name